CJC-1295 no DAC

CJC-1295 no DAC: A no-DAC GHRH analogue commonly described as modified GRF 1-29.

What is it?

A no-DAC GHRH analogue commonly described as modified GRF 1-29.

How it is studied

The peptide is studied through the growth-hormone-releasing hormone pathway. It does not contain the DAC form’s albumin-binding extension.

What the evidence says

Frequently cited CJC-1295 clinical literature concerns the DAC molecule. Those pharmacokinetic findings are not direct evidence for the no-DAC material.

What remains uncertain

The two forms must not share half-life or efficacy assumptions. Human outcome evidence for this exact material is limited. The Standard lists only the no-DAC version.

Sources & scope

Long-acting CJC-1295 study (2006)

For in-vitro laboratory research only. Not for human or veterinary use.